Hana Janouskova
Research scientist
Research scientist
Oncology Institute of Southern Switzerland
Switzerland
Biography
post-Doctoral from Oncology Research (IOR), Bellinzona-Switzerland. PhD from University of Strasbourg,France.
Research Interest
Molecular Biology, Cancer Biology, Targeted Therapy, Bromodomain proteins, Protein Degradation, Endometrial cancer, Glioblastoma pathology, Prostate cancer, p53 Pathway and working on a paradoxical paradigm in oncogenomics, whereby mutations within the same domain of a particular gene evoke opposing drug susceptibilities
Publications
-
Janouskova H, Maglott A, Leger DY, Bossert C, Noulet F, Guérin E, Guenot D, Pinel S, Chastagner P, Plénat F, Entz-Werlé N. Is nutlin-3A a new therapeutic option for a subset of high grade glioma expressing a wild type P53 and high α5β1 integrin?. In2ème Colloque Inter-régional Grand-Est de Recherche Translationnelle en Oncologie, ONCOTRANS 2011 2011 Sep 8.
-
Janouskova H, Ray AM, Noulet F, Lelong-Rebel I, Choulier L, Schaffner F, Lehmann M, Martin S, Teisinger J, Dontenwill M. Activation of p53 pathway by Nutlin-3a inhibits the expression of the therapeutic target α5 integrin in colon cancer cells. Cancer letters. 2013 Aug 19;336(2):307-18.
-
Janouskova H, Maglott A, Leger DY, Bossert C, Noulet F, Guerin E, Guenot D, Pinel S, Chastagner P, Plenat F, Entz-Werle N. Integrin α5β1 plays a critical role in resistance to temozolomide by interfering with the p53 pathway in high-grade glioma. Cancer research. 2012 Jul 15;72(14):3463-70.
